| A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease (NCT03375697) | Janssen Research & Development, LLC | 2017-12-22 |
| Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (NCT03399799) | Janssen Research & Development, LLC | 2017-12-16 |
| A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy (NCT03321526) | Janssen Research & Development, LLC | 2017-12-12 |
| A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma (NCT03234972) | Janssen Research & Development, LLC | 2017-11-30 |
| A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus (NCT03333317) | Janssen Research & Development, LLC | 2017-11-24 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder (NCT03375203) | Janssen Research & Development, LLC | 2017-11-23 |
| A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region) (NCT03217812) | Janssen Research & Development, LLC | 2017-11-23 |
| A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy (NCT03404791) | Janssen Research & Development, LLC | 2017-11-20 |
| A Study of Paliperidone Palmitate 6-Month Formulation (NCT03345342) | Janssen Research & Development, LLC | 2017-11-20 |
| A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events (NCT03479736) | Janssen Research & Development, LLC | 2017-11-20 |
| A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma (NCT03357952) | Janssen Research & Development, LLC | 2017-11-16 |
| A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants (NCT03346122) | Janssen Research & Development, LLC | 2017-11-15 |
| A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery (NCT03251482) | Janssen Research & Development, LLC | 2017-11-13 |
| An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin (NCT03267576) | Janssen Research & Development, LLC | 2017-10-27 |
| A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy (NCT03301207) | Janssen Research & Development, LLC | 2017-10-20 |
| A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes (NCT03298542) | Janssen Research & Development, LLC | 2017-10-16 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants (NCT03320707) | Janssen Research & Development, LLC | 2017-10-16 |
| Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide (NCT03185819) | Janssen Research & Development, LLC | 2017-10-05 |
| A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis (NCT03201965) | Janssen Research & Development, LLC | 2017-10-05 |
| A Study to Assess the Effect of Ticlopidine on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants (NCT03298906) | Janssen Research & Development, LLC | 2017-09-26 |
| A Study to Evaluate Bioequivalence and Adhesion of a Transdermal Contraceptive Patch Manufactured With Newly Sourced Adhesive Components and Currently Marketed EVRA in Healthy Adult Women (NCT03274297) | Janssen Research & Development, LLC | 2017-09-20 |
| A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]JNJ-64511070 (NCT03270579) | Janssen Research & Development, LLC | 2017-09-12 |
| A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function (NCT03277755) | Janssen Research & Development, LLC | 2017-09-11 |
| Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants (NCT03239561) | Janssen Research & Development, LLC | 2017-09-06 |